Literature DB >> 17804754

Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells.

Naotake Tsuda1, David Z Chang, Takashi Mine, Clay Efferson, Adolfo García-Sastre, Xinhui Wang, Soldano Ferrone, Constantin G Ioannides.   

Abstract

It has been proposed that chemotherapy enhances tumor antigen (TA)-specific immunity. The molecular form of TA from ovarian tumor that activates cellular immunity is unknown. We report here identification of a novel molecular form of immunogenic TA for CD8(+) cells named self-immune stimulatory multimolecular complexes (ISMMC). ISMMC consist of a molecular complex of polyosome/ribosome-bound ubiquitinated nascent HER-2 polypeptides. This complex is chaperoned by heat shock protein Gp96, which mediates ISMMC uptake by antigen-presenting cells through the scavenger receptor CD91. RNAs in ISMMC stimulate immature dendritic cells to secrete interleukin 12 and induce IFN-gamma in peripheral blood mononuclear cells. ISMMC dissociate, retrotranslocate from the lysosome to cytoplasm, and are processed to peptides by the proteasome. At subpharmacologic doses, Taxol increased the amount of ISMMC by three to four times and modified their composition by inducing the attachment of cochaperones of HSP70, such as the mitotic-phase phosphoprotein 11J. On a total protein basis, Taxol induced ISMMC, expanded more CD8(+) cells, activated more CD56(+) NKG2D(+) cells to produce IFN-gamma, and were more potent inducers of high T-cell receptor density Perforin(+) cells than native ISMMC and peptide E75. Elucidation of the composition of ISMMC and identification of adducts formed by Taxol should be important for developing molecular cancer vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804754     DOI: 10.1158/0008-5472.CAN-07-0327

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.

Authors:  Lukas W Pfannenstiel; Samuel S K Lam; Leisha A Emens; Elizabeth M Jaffee; Todd D Armstrong
Journal:  Cell Immunol       Date:  2010-03-06       Impact factor: 4.868

2.  Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells.

Authors:  Takashi Mine; Satoko Matsueda; Hui Gao; Yufeng Li; Kwong-Kwok Wong; George E Peoples; Soldano Ferrone; Constantin G Ioannides
Journal:  Oncol Rep       Date:  2010-06       Impact factor: 3.906

3.  Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients.

Authors:  Romain Remark; Audrey Lupo; Marco Alifano; Jerome Biton; Hanane Ouakrim; Alessandro Stefani; Isabelle Cremer; Jeremy Goc; Jean-Francois Régnard; Marie-Caroline Dieu-Nosjean; Diane Damotte
Journal:  Oncoimmunology       Date:  2016-12-08       Impact factor: 8.110

Review 4.  Host tissue determinants of tumour immunity.

Authors:  Hélène Salmon; Romain Remark; Sacha Gnjatic; Miriam Merad
Journal:  Nat Rev Cancer       Date:  2019-04       Impact factor: 60.716

Review 5.  The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.

Authors:  Daniel R Principe; Suneel D Kamath; Murray Korc; Hidayatullah G Munshi
Journal:  Pharmacol Ther       Date:  2022-01-10       Impact factor: 13.400

6.  Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.

Authors:  Takashi Mine; Satoko Matsueda; Yufeng Li; Hiroshi Tokumitsu; Hui Gao; Cristopher Danes; Kwong-Kwok Wong; Xinhui Wang; Soldano Ferrone; Constantin G Ioannides
Journal:  Cancer Immunol Immunother       Date:  2008-12-02       Impact factor: 6.968

7.  Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines.

Authors:  Chih-Chun Wen; Hui-Ming Chen; Swey-Shen Chen; Li-Ting Huang; Wei-Ting Chang; Wen-Chi Wei; Li-Chen Chou; Palanisamy Arulselvan; Jin-Bin Wu; Sheng-Chu Kuo; Ning-Sun Yang
Journal:  J Biomed Sci       Date:  2011-06-20       Impact factor: 8.410

Review 8.  nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors.

Authors:  Hatem H Soliman
Journal:  Onco Targets Ther       Date:  2016-12-21       Impact factor: 4.147

9.  Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes.

Authors:  M Stumpf; A Hasenburg; M-O Riener; U Jütting; C Wang; Y Shen; M Orlowska-Volk; P Fisch; Z Wang; G Gitsch; M Werner; S Lassmann
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

10.  Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.

Authors:  Katy Milne; Rebecca O Barnes; Adam Girardin; Melanie A Mawer; Nancy J Nesslinger; Alvin Ng; Julie S Nielsen; Robert Sahota; Eric Tran; John R Webb; May Q Wong; Darin A Wick; Andrew Wray; Elissa McMurtrie; Martin Köbel; Steven E Kalloger; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2008-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.